{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115069","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.563128+00:00","generated_at":"2026-05-30T03:28:26.796907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Carisma Q3 net loss $12.7M; cash $26.9M; CT-0525 initial data expected Q1 2025","bullets":["Net loss of $12.7M in Q3 2024 vs $21.4M in Q3 2023; R&D expenses fell to $11.3M from $19.6M.","Cash and equivalents $26.9M as of Sep 30, 2024, down from $40.4M at Jun 30; expected runway into Q3 2025.","Phase 1 CT-0525 (HER2 CAR-Monocyte) initial data for Cohorts 1 and 2 expected Q1 2025; protocol amended for repeat dosing with pembrolizumab.","Expanded Moderna collaboration to include two autoimmune targets; retains rights beyond those.","Liver fibrosis development candidate nomination expected Q1 2025; preclinical data to be presented at AASLD."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115069","json":"https://secwatch.observer/filing/0001104659-24-115069.json","markdown":"https://secwatch.observer/filing/0001104659-24-115069.md","text":"https://secwatch.observer/filing/0001104659-24-115069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924115069/0001104659-24-115069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924115069/tm2426977d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:28:26.796907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}